Trial Profile
A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 12 Jun 2015 Results published in the Diabetologia.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 04 May 2012 Actual patient number is 75 according to ClinicalTrials.gov record (Extension trial; NCT00770081).